The 7,000 square foot facility will serve the firm’s clinical R&D, production and sales operations as part of the Japanese drugmakers efforts to consolidate its European operations.
In a press statement Eisai said that it considers the local scientific expertise and experience as key to its expansion plans in European drug market.
